Window of Opportunity Study of DSP-0390 in Gliomas

NCT06636162 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Glioma, Malignant
IDH Mutation

Interventions

DRUG: DSP-0390

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]